Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Structure-Cytotoxicity Relationships of Analogues of N14-Desacetoxytubulysin H.

Toader D, Wang F, Gingipalli L, Vasbinder M, Roth M, Mao S, Block M, Harper J, Thota S, Su M, Ma J, Bedian V, Kamal A.

J Med Chem. 2016 Dec 8;59(23):10781-10787. Epub 2016 Nov 16.

PMID:
27809515
2.

Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.

Williams GS, Mistry B, Guillard S, Ulrichsen JC, Sandercock AM, Wang J, González-Muñoz A, Parmentier J, Black C, Soden J, Freeth J, Jovanović J, Leyland R, Al-Lamki RS, Leishman AJ, Rust SJ, Stewart R, Jermutus L, Bradley JR, Bedian V, Valge-Archer V, Minter R, Wilkinson RW.

Oncotarget. 2016 Oct 18;7(42):68278-68291. doi: 10.18632/oncotarget.11943.

3.

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.

Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, Bannister D, Dick E, Crawford N, Parmentier J, Alimzhanov M, Babcook JS, Foltz IN, Buchanan A, Bedian V, Wilkinson RW, McCourt M.

Cancer Immunol Res. 2015 Sep;3(9):1052-62. doi: 10.1158/2326-6066.CIR-14-0191. Epub 2015 May 5.

4.

Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling.

Michaud NR, Wang Y, McEachern KA, Jordan JJ, Mazzola AM, Hernandez A, Jalla S, Chesebrough JW, Hynes MJ, Belmonte MA, Wang L, Kang JS, Jovanovic J, Laing N, Jenkins DW, Hurt E, Liang M, Frantz C, Hollingsworth RE, Simeone DM, Blakey DC, Bedian V.

Mol Cancer Ther. 2014 Feb;13(2):386-98. doi: 10.1158/1535-7163.MCT-13-0420. Epub 2013 Dec 16.

5.

Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.

Laing N, McDermott B, Wen S, Yang D, Lawson D, Collins M, Reimer C, Hall PA, Andersén H, Snaith M, Wang X, Bedian V, Cao ZA, Blakey D.

Mol Pharmacol. 2013 Jun;83(6):1247-56. doi: 10.1124/mol.112.084079. Epub 2013 Apr 4.

PMID:
23558446
6.

Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression.

Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, Popovic B, Bishop SM, Dall'Acqua W, Minter R, Jermutus L, Bedian V.

MAbs. 2013 Mar-Apr;5(2):255-62. doi: 10.4161/mabs.23392. Epub 2013 Feb 14.

7.

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.

Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross SJ, Rooney C, Smith NR, Rinkenberger J, Cao A, Churchman A, Marshall JF, Weir HM, Bedian V, Blakey DC, Foltz IN, Barry ST.

Oncogene. 2013 Sep 12;32(37):4406-16. doi: 10.1038/onc.2012.460. Epub 2012 Oct 29.

PMID:
23108397
8.

Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.

Michaud NR, Jani JP, Hillerman S, Tsaparikos KE, Barbacci-Tobin EG, Knauth E, Putz H Jr, Campbell M, Karam GA, Chrunyk B, Gebhard DF, Green LL, Xu JJ, Dunn MC, Coskran TM, Lapointe JM, Cohen BD, Coleman KG, Bedian V, Vincent P, Kajiji S, Steyn SJ, Borzillo GV, Los G.

MAbs. 2012 Nov-Dec;4(6):710-23. doi: 10.4161/mabs.22160. Epub 2012 Sep 24.

9.

MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.

Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST.

Mol Cancer Ther. 2012 Aug;11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027. Epub 2012 Jun 7.

10.

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.

Gladue RP, Paradis T, Cole SH, Donovan C, Nelson R, Alpert R, Gardner J, Natoli E, Elliott E, Shepard R, Bedian V.

Cancer Immunol Immunother. 2011 Jul;60(7):1009-17. doi: 10.1007/s00262-011-1014-6. Epub 2011 Apr 12.

PMID:
21479995
11.

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.

Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC.

Mol Cancer Ther. 2010 Jan;9(1):145-56. doi: 10.1158/1535-7163.MCT-09-0554. Epub 2010 Jan 6.

13.

Development and validation of radioligand binding assays to measure total, IgA, IgE, IgG, and IgM insulin antibodies in human serum.

Moxness M, Foley J, Stene M, Finco-Kent D, Bedian V, Krasner A, Kawabata T.

Ann N Y Acad Sci. 2003 Nov;1005:265-8.

PMID:
14679073
14.

Development and validation of a radioligand binding assay to measure insulin specific IgG subclass antibodies in human serum.

Finco-Kent D, Morrone A, Moxness M, Bedian V, Krasner A, Foley J, Stene M, Kawabata T.

Ann N Y Acad Sci. 2003 Nov;1005:259-64.

PMID:
14679072
15.
16.

Neuroanatomical studies of period gene expression in the hawkmoth, Manduca sexta.

Wise S, Davis NT, Tyndale E, Noveral J, Folwell MG, Bedian V, Emery IF, Siwicki KK.

J Comp Neurol. 2002 Jun 10;447(4):366-80.

PMID:
11992522
17.

Self-description and the origin of the genetic code.

Bedian V.

Biosystems. 2001 Apr-May;60(1-3):39-47.

PMID:
11325502
18.

Monoclonal antibodies in the analysis of embryonic development.

Bedian V.

Methods Mol Biol. 2000;137:159-66. No abstract available.

PMID:
10948535
19.

Isolation and characterization of monoclonal antibodies directed against novel components of macrophage phagosomes.

Morrissette NS, Gold ES, Guo J, Hamerman JA, Ozinsky A, Bedian V, Aderem AA.

J Cell Sci. 1999 Dec;112 ( Pt 24):4705-13.

20.

Rump white inversion in the mouse disrupts dipeptidyl aminopeptidase-like protein 6 and causes dysregulation of Kit expression.

Hough RB, Lengeling A, Bedian V, Lo C, Bućan M.

Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13800-5.

21.

A gene belonging to the Sm family of snRNP core proteins maps within the mouse MHC.

Bedian V, Adams T, Geiger EA, Bailey LC, Gasser DL.

Immunogenetics. 1997;46(5):427-30. No abstract available.

PMID:
9271633
22.

Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies.

Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH Jr.

Blood. 1996 Nov 1;88(9):3446-50.

PMID:
8896409
24.

Monoclonal antibody X18A4 identifies an oncofetal fibronectin epitope distinct from the FDC-6 binding site.

Feinberg RF, Kliman HJ, Bedian V, Monzon-Bordonaba F, Menzin AW, Wang CL.

Am J Obstet Gynecol. 1995 May;172(5):1526-36.

PMID:
7538728
26.

Characterization of extreme apical antigens from Toxoplasma gondii.

Morrissette NS, Bedian V, Webster P, Roos DS.

Exp Parasitol. 1994 Nov;79(3):445-59.

PMID:
7525339
27.
28.

Kinase activity and genetic characterization of a growth related antigen of Drosophila.

Bedian V, Jungklaus CE, Cardoza L, von Kalm L.

Dev Genet. 1991;12(3):188-95.

PMID:
1868624
29.

Kinase inhibition lengthens the period of the circadian pacemaker in the eye of Bulla gouldiana.

Roberts MH, Bedian V, Chen YL.

Brain Res. 1989 Dec 18;504(2):211-5.

PMID:
2598024
30.
31.

Expression of the differentiation antigen F7D6 in tumorous tissues of Drosophila.

Bedian V, Jungklaus CE.

Dev Genet. 1987;8(3):165-77.

PMID:
3502971
32.

Supplemental Content

Loading ...
Support Center